CUMBERLAND PHARMACEUTICALS ANNOUNCES NATIONAL CALL TO PRESENT AN UPDATE ON ITS IFETROBAN DMD PROGRAM
CUMBERLAND PHARMACEUTICALS ANNOUNCES NATIONAL CALL TO PRESENT AN UPDATE ON ITS IFETROBAN DMD PROGRAM
PR Newswire
NASHVILLE, Tenn., Oct. 19, 2026
NASHVILLE, Tenn., Oct. 19, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, announced today that it will provide an update on its ifetroban product candidate in development as a potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy ("DMD").
A national webcasting event and conference call will be held on Monday, October 26th at 4:30 p.m. Eastern Time to provide the update. Participants may join the presentation via webcast, to view the accompanying slides, or by conference call for audio-only access.
Webcast Participation
The link to register for the webcast participation is:
https://edge.media-server.com/mmc/p/e4k38y5q
Call Participation
The link to register for the conference call participation is:
https://register-conf.media-server.com/register/BI5f9f9d5a8fef425b99857a39138a38e9
Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.
Presentation Copy
A copy of the presentation will be available and can be accessed via the Investor Relations page of the Cumberland Pharmaceuticals website at: https://investor.cumberlandpharma.com/events-presentations
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is an innovation-driven biopharmaceutical company developing new therapies to address significant unmet medical needs and improve patient outcomes.
Cumberland's clinical programs are evaluating ifetroban in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Cancer Metastasis.
For more information, please visit www.cumberlandpharma.com
SOURCE Cumberland Pharmaceuticals Inc.
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
Why This Vanguard ETF Is One of the Best
6 ETFs To Diversify Away From AI
The Best AI Stocks to Buy Now
United States